Jaguar Health Reports 2019 Financial Results and Business Updates Mytesi net sales and gross sales grew 38% and 44%, respectively, in 2019 compared to 2018 Reminder: Company to host investor call Monday, April 6 at 8:30

Jaguar Health Reports 2019 Financial

Results and Business Updates

Mytesi net sales and

gross sales grew 38% and 44%, respectively, in 2019 compared to 2018

Reminder: Company to host investor call

Monday, April 6 at 8:30 a.m. Eastern

SAN FRANCISCO, CA / April 6, 2020 / Jaguar Health,

Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year

ended December 31, 2019 and provided business updates.

"We are very pleased to see strong Mytesi

(crofelemer) sales growth in 2019 over 2018," Lisa Conte, Jaguar's president and CEO, commented. "Looking forward,

we believe 2020 has the potential to be a transformative year for the Company. Our core goals for the year include forging a regional,

ex-US business development deal to bring in non-dilutive dollars to support efforts to move key potential Mytesi pipeline indications

into development, commercialization, and access outside the U.S., and completing the roll-out of our new, recently announced patient

support program for Mytesi. Subject to additional financing, we are also planning to initiate three clinical trials in the second

half of 2020 - a pivotal trial for the indication of prevention and treatment of cancer therapy-related diarrhea (CTD) in

adult cancer patients, and two studies for the rare pediatric disease indications of congenital diarrheal disease and short bowel

syndrome. For the adult CTD study, we've been in active discussions with the FDA, and in meetings with key opinion leaders,

and have received their input on the clinical trial and statistical analysis plan. We are revising the clinical protocol to accommodate

their input and preparing the requisite documents including the statistical analysis plan, the informed consent and other requirements

to initiate this pivotal adult CTD trial under a new IND. The principal investigator is at a major cancer institution in the US.

Finally, at a time when the world is grappling with a pandemic, we are pleased to announce that our wholly owned subsidiary, Napo

Pharmaceuticals, will receive additional preclinical services from the National Institute of Allergy and Infectious Diseases ("NIAID")

to support development of lechlemer, Napo's second generation, plant-based anti-secretory drug candidate for treatment of

diarrhea associated with the enduring scourge of cholera. Under NIAID's suite of preclinical services, NIAID-funded contractors

will conduct toxicology testing for a 28-day rat study. NIAID is part of the National Institutes of Health."

2019 Company Financial Results:

Note Regarding Use of Non-GAAP Measures

The Company supplements its condensed consolidated financial

statements presented on a GAAP basis by providing gross sales, non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered

non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with

additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP

financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and

GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.

Gross sales percentages issued by the Company are based on gross

sales figures that represent Mytesi orders placed by wholesalers with Jaguar's third-party logistics warehouse, which generate

invoiced sales and cash flow for Napo. Gross sales is used internally by management as an indicator of and to monitor operating

performance, including sales performance of Mytesi, salesperson performance, and product growth or declines. The Company believes

that the presentation of gross sales provides a closer to real-time useful measure of our operating performance. Gross sales is

not a measure that is recognized under accounting principles generally accepted in the United States of America ("GAAP")

and should not be considered as an alternative to net sales, which is determined in accordance with GAAP, and should not be used

alone as an indicator of operating performance in place of net sales. Additionally, gross sales may not be comparable to similarly

titled measures used by other companies, as gross sales have been defined by the Company's internal reporting practices.

In addition, gross sales may not be realized in the form of cash receipts as promotional payments and allowances may be deducted

from payments received from certain customers. Mytesi gross sales are reduced by Medicare, ADAP 340B chargebacks, returns, and

wholesale distribution fees based on historical trends to determine net sales.

The Company defines non-GAAP EBITDA as net loss before interest

expense and other expense, property and equipment, amortization of intangible assets, share-based compensation expense and provision

for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring

revenues and expenses, such as a non-recurring adjustment related to a donation. Company management believes that non-GAAP EBITDA

and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar's performance and provide useful information to investors

regarding the Company's results of operations and financial condition.

Dial-In Instructions for Conference Call

When: April 6, 2020 at 8:30 a.m. Eastern

Dial-in (US Toll Free): 888-394-8218

Dial-in (International): 323-701-0225

Conference ID number: 7352525

Live webcast on the investor relations

section of Jaguar's website (click here)

Dial-in (US Toll Free): 844-512-2921

Dial-in (International): 412-317-6671

Replay Pin Number: 7352525

Replay of the webcast on the investor relations

section of Jaguar's website (click here)

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals

company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly owned

subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal

pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi

(crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS

on antiretroviral therapy.

For more information about Jaguar, please visit Jaguar.health.

For more information about Napo, visit napopharma.com.

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic

relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the

treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are

not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease

may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory

tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer,

the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal

Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to

ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking

statements." These include statements regarding the belief that 2020 has the potential to be a transformative year for the

Company, the Company's goal of forging an ex-US business development deal to bring in non-dilutive dollars to support efforts

to move key potential Mytesi pipeline indications into development, commercialization, and access outside the U.S., the Company's

plans to complete the roll-out of its new patient support program for Mytesi, plans to initiate three clinical trials in the second

half of 2020, subject to additional financing, the expectation that Napo will receive additional preclinical services from NIAID

to support development of lechlemer, and the expectation that the Company will host an investor call on April 6, 2020. In some

cases, you can identify forward-looking statements by terms such as "may," "will," "should,"

"expect," "plan," "aim," "anticipate," "could," "intend,"

"target," "project," "contemplate," "believe," "estimate," "predict,"

"potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking

statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations

and projections about future events. These forward-looking statements speak only as of the date of this release and are subject

to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond